Issue 7 / Week of 14-20 July 2026

Read the milestones. That is where the story is.

On 16 July, Eli Lilly agreed to buy AtaiBeckley Inc. This is a share acquisition, not an asset grab: $6.75 per share in cash at closing, roughly $2.8 billion, plus a contingent value right worth up to $2.50 per share, roughly another $1.0 billion, for a headline of up to $3.8 billion. The CVR is where Lilly says what it actually values, and it says it in three lines: $1.00 per share on initiation of a Phase 3 trial of VLS-01 before the fourth anniversary of closing; $0.50 per share on US regulatory approval and DEA rescheduling of BPL-003 before the fifth anniversary; $1.00 per share on US regulatory approval and DEA rescheduling of VLS-01 before the seventh anniversary. BPL-003 is intranasal 5-MeO-DMT, mebufotenin benzoate, for treatment-resistant depression. VLS-01 is a buccal-film DMT in Phase 2b.

Read that carefully. Every approval trigger names the FDA and the DEA. Not one names the EMA, the European Union, or a single European market. The world's most valuable pharma company wrote a billion dollars of incentives for its own dealmakers and defined winning as a US approval plus a US scheduling decision, full stop. If you are structuring milestones your own staff get paid on, you point them where the money clears fastest, and that is not Europe.

But "not worth a Lilly milestone" is not the same as "not worth building." Those are two different sentences and the whole reason this newsletter exists sits in the gap between them. Ketamine-assisted clinics are growing across German-speaking Europe, and demand is not shrinking. The depression burden is not shrinking. And the question of how, and whether, Europeans actually get access to this class of medicine is now a question nobody with Lilly-sized money has any incentive to answer. Lilly just told you, in a legal document, that it will not be the one to answer it. That gap is the beat we cover.

Europe getting medicines last is not a grievance. It is documented, and it is structural.

The EFPIA W.A.I.T. 2025 report is blunt about it. Of 168 medicines tracked, close to half, 49 percent, were not available to European patients as of 2025. The median wait from approval to patient access was 532 days, and that median hides a chasm: 56 days in Germany, 1,201 days in Romania. Zoom out and the commercial gravity is just as one-sided. Europe accounts for 15.6 percent of global new-active-substance sales. The US accounts for 74.1 percent.

A psychedelic does not get a special lane through that machine. It enters the same one. Whatever Compass, or a Lilly-owned AtaiBeckley, eventually launches in the US on a single approval will then have to be priced and reimbursed one national payer at a time, in the slowest and least commercially attractive of the major markets. The milestone structure in the Lilly deal is not an anomaly. It is that reality, written down.

Compass says the quiet part: the therapy may not be the point. On 16 July, Compass Pathways published a post-hoc analysis in the Journal of Psychopharmacology arguing that the psychological support in its COMP360 trials is not psychotherapy. The finding it leans on: 78 percent of the dosing session was spent in silence. Guy Goodwin, its chief medical officer, put it flatly: "It is incorrect to describe the treatment we are developing as psilocybin-assisted psychotherapy."

Notice the motive before you weigh the claim. Compass has a direct commercial interest in arguing the drug does the work and the therapist does not, because billable therapist hours are exactly the cost that makes this category hard to scale and hard to reimburse. But here is the twist worth holding: if the claim holds up, it is quietly good news for European access, not bad. Therapist time is precisely what EU payers choke on. A protocol that is drug-plus-monitoring rather than drug-plus-therapy is cheaper to deliver and easier to reimburse. The problem is what the argument rests on: a single open-label Phase 2 study in PTSD, analyzed after the fact, in trials that still used trained clinicians to monitor patients. Silence in the room is not the same as no clinician in the building. The truth almost certainly sits in between, and Compass has every reason to stand on the end of it that lowers its own cost of goods.

AtaiBeckley's European footprint is thinner than the buyout implies. Here is what Lilly is actually buying in Europe, from the registry rather than the press release. As of this week's ClinicalTrials.gov records, the live recruiting trials carry European sites in the United Kingdom only: BPL-003 in TRD (NCT05660642) and VLS-01's ELUMINA study in TRD (NCT06524830). The EU-member-state sites, Germany, Poland and Spain, sit in the BPL-003 Phase 2b that is already completed (NCT05870540). And neither drug has a registered Phase 3, for any indication, in any country. Worth one flag: Lilly's own release says BPL-003 has "initiated Phase 3 activities," but the registry shows only Phase 2. Activities are not a trial, and until a Phase 3 posts, the record says Phase 2. Under a deal whose milestones reward US approval and nothing else, there is no financial reason that European footprint grows.

One. The number of newly registered European-origin clinical trials in psychedelic and psychedelic-adjacent medicine we logged all week: a single Dutch study of IV ketamine-assisted psychotherapy in treatment-resistant depression, sponsored by Senz, first posted to ClinicalTrials.gov on 15 July (NCT07706478, recruiting, Netherlands). One small trial from the Netherlands, in the same seven days that the largest pharmaceutical company on earth spent up to $3.8 billion on the category and wrote Europe out of every milestone. The imbalance is the point. The money is American, the approval pathway it is chasing is American, and the one piece of new European clinical activity is a single national trial with no industry giant behind it.

EU / EMA: Neither BPL-003 nor VLS-01 has a disclosed EMA pathway, and the Lilly deal names none. The centralised procedure would give either drug one marketing authorisation valid across all EU and EEA states, but the EMA has no role in price. That stays national. The Joint Clinical Assessment framework, in force since January 2025, harmonises the clinical review, not the reimbursement decision, which remains country-by-country. So the single-approval efficiency Europe does offer stops exactly at the point where money changes hands.

US / FDA + DEA: The deal makes the dependency explicit. Two of the three milestones require not just FDA approval but DEA rescheduling, the same slow, separate federal step we have flagged on Compass. Lilly has now attached hard money to clearing it twice.

UK: The only live European trial sites AtaiBeckley is bringing to Lilly are here, not in the EU. Post-Brexit, that is European exposure that routes around the EMA entirely.

Scoring the open calls. Four calls are live and none has resolved. Issue 3's call, that AtaiBeckley reports its first BPL-003 Phase 3 patient dosed in Q3 2026, resolves on 30 September; open, and note the tension with this week, since a Q3 dosing needs a Phase 3 that the registry still does not show. Issue 4's call, that Definium's Panorama posts a smaller placebo-adjusted effect than its sister trial Voyage, resolves once both GAD toplines are public; neither has read out; open. Issue 5's call, that BPL-003's Phase 3, when it registers, uses an adjunctive design with no SSRI washout, resolves when the protocol posts, expected H2 2026; still unregistered, so open. Issue 6's call, that COMP360 is not commercially available to prescribe in the US by 30 June 2027, resolves on that date; open. Nothing due this week, nothing to score.

This week's call. Within 12 months of the Lilly deal closing, neither BPL-003 nor VLS-01 will have a registered Phase 3 trial carrying a single EU-member-state site, and Lilly will have announced no EMA pathway for either drug. This is our read, not Lilly's stated plan: the company has not said it is abandoning Europe, and we are not reporting that it has. We are calling what its own milestone structure implies. If the incentives point only at the FDA and the DEA, the European clinical footprint stays where it is, in the UK and in already-completed trials, and the EMA question goes unanswered. Falsifiable and checkable: if a Phase 3 for either drug registers with any EU-member-state site, or Lilly discloses an EMA pathway for either, within the window, we are wrong.

Resolve: 12 months after the acquisition closes. If no closing date is made public, treat 21 July 2027 as the backstop.

If something here is wrong, let me know, and I will correct it openly.

Thank you so much for reading.

Dhruv Shekhawat